#5-41E. Targeting Selective Pathways: 52-Week Efficacy and Safety of Deucravacitinib in Psoriatic Arthritis (Arthritis Rheumatol, 2026)

How can clinicians better manage the complex musculoskeletal and dermatologic manifestations of psoriatic arthritis with an oral option? The Phase 3 POETYK PsA-2 trial investigated the efficacy and safety of deucravacitinib, a first-in-class, selective oral TYK2 inhibitor, randomized against placebo and apremilast in patients with active psoriatic arthritis. At week 16, significantly more patients achieved ACR20 with deucravacitinib than placebo (54.2% versus 39.4%), with clinical and patient-reported improvements sustained or enhanced up to week 52. Its selective allosteric mechanism of action targets key cytokine pathways without triggering the off-target safety signals traditionally associated with JAK inhibitors. However, clinicians must critically consider that only 13.4% of participants had prior tumor necrosis factor inhibitor experience, and the study population was highly homogeneous, being predominantly White and over forty-five, which may limit generalizability to refractory or diverse real-world cohorts. Nonetheless, POETYK PsA-2 provides pivotal evidence for a well-tolerated, durable oral therapy, empowering physicians to address multiple psoriatic arthritis domains effectively.

Citation: Philip J. Mease, et al. Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial. Arthritis & Rheumatology. 2026. DOI: 10.1002/art.70280

URL: https://doi.org/10.1002/art.70280

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.